Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer

DSpace/Manakin Repository

Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer

Citable link to this page

 

 
Title: Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer
Author: Dagoglu, Nergiz; Callery, Mark; Moser, James; Tseng, Jennifer; Kent, Tara; Bullock, Andrea; Miksad, Rebecca; Mancias, Joseph D.; Mahadevan, Anand

Note: Order does not necessarily reflect citation order of authors.

Citation: Dagoglu, Nergiz, Mark Callery, James Moser, Jennifer Tseng, Tara Kent, Andrea Bullock, Rebecca Miksad, Joseph D. Mancias, and Anand Mahadevan. 2016. “Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer.” Journal of Cancer 7 (3): 283-288. doi:10.7150/jca.13295. http://dx.doi.org/10.7150/jca.13295.
Full Text & Related Files:
Abstract: Objectives: After adjuvant or definitive radiation for pancreas cancer, there are limited conventional treatment options for recurrent pancreas cancer. We explored the role of (Stereotactic Body Radiotherapy) SBRT for reirradiation of recurrent pancreas Cancer. Methods: This is a retrospective study of patients reirradiated with SBRT for recurrent pancreas cancer. All patients were deemed unresectable and treated with systemic therapy. Fiducial gold markers were used. CT simulation was performed with oral and IV contrast and patients were treated with respiratory motion tracking in the CyberknifeTM system. Results: 30 patients (17 men and 13 women) with a median age of 67 years were included in the study. The median target volume was 41.29cc. The median prescription dose was 25Gy (24-36Gy) in a median of 5 fractions prescribed to a mean 78% isodose line. The median overall survival was 14 months. The 1 and 2 year local control was 78%. The worst toxicity included 3/30(10%) Grade III acute toxicity for pain, bleeding and vomiting. There was 2/30 (7%) Grade III long-term bowel obstructions. Conclusions: SBRT can be a useful and tolerable option for patients with recurrent pancreas cancer after prior radiation.
Published Version: doi:10.7150/jca.13295
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747882/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:25658345
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters